Core Insights - Haichuang Pharmaceutical achieved significant revenue growth in the first three quarters of 2025, with a reported revenue of 23.35 million yuan, representing a year-on-year increase of 21,180.28% [1] - The company reported a net loss attributable to shareholders of 99.15 million yuan, a substantial reduction from a loss of 154 million yuan in the same period last year [1] - The approval and commercialization of the first-class new drug, Dihenzalutamide, in May 2025 marked a pivotal moment for the company, indicating a successful transition from the investment phase to the return phase [1][2] Revenue Growth and Market Strategy - The significant revenue increase is attributed to the successful market launch of Dihenzalutamide, which has become a key revenue driver for the company [1] - Haichuang Pharmaceutical employs a dual-track model of "self-operated + CSO (Contract Sales Organization)" and a four-wheel drive strategy encompassing "medical-market-access-sales" to rapidly capture market opportunities [2] - The company has established an efficient sales network covering over 500 hospitals and 240 DTP pharmacies across 30 provinces, laying a solid foundation for the rapid growth of new drug sales [2] Product Development and Clinical Trials - Dihenzalutamide has been included in the 2025 edition of the CSCO Prostate Cancer Diagnosis and Treatment Guidelines, enhancing its market recognition [2] - The product is undergoing preliminary review for inclusion in the national medical insurance directory, which, if successful, will significantly improve drug accessibility and accelerate market penetration [2] - In the metabolic disease sector, the company is advancing its key product HP515, which targets obesity and metabolic-associated fatty liver disease (MASH), with promising results from Phase I clinical trials [3] Future Prospects - The development path for HP515 focuses on three main areas: combination therapy with GLP-1 for MASH, combination therapy for obesity, and exploring its use with the company's own oral small molecule GLP-1 receptor agonist [3] - The company is expected to continue expanding its revenue scale and gradually reduce net profit losses as new drugs progress through commercialization [3] - With its innovative technology and forward-looking pipeline, Haichuang Pharmaceutical is positioned to secure a significant place in the biopharmaceutical sector [3]

Core Viewpoint - Haichuang Pharmaceutical's first innovative drug, Deuteroenzalutamide soft capsule, reported a revenue of 10.18 million yuan for the quarter, a 22.65% decrease from the previous quarter, and a net loss of 37.29 million yuan, down 25.35% quarter-on-quarter but narrowed by 30% year-on-year [2][3][4]. Financial Performance - Revenue for the quarter was 10.18 million yuan, a significant drop from 13.16 million yuan in June, indicating a failure to maintain growth [4]. - The total profit for the period was -37.29 million yuan, with a basic earnings per share of -0.38 yuan [5][8]. - Cash flow from operating activities showed a net outflow of 32.28 million yuan, primarily due to employee payments and market promotion expenses [8]. Cost Structure - Sales expenses reached 15.19 million yuan, a 218.68% increase year-on-year, leading to a high expense ratio of 606.44% [6]. - Despite a decrease in R&D expenses, the overall cost structure remains burdensome, impacting profitability [6]. Market and Product Pipeline - The company has strategically adjusted its pipeline, halting further development of the HP501 project due to intense competition in the URAT1 target market [10][11]. - The ongoing clinical trial for HP515 is expected to face significant market challenges, similar to those encountered by the abandoned HP501 project [11]. - The competitive landscape for Deuteroenzalutamide is intense, with the prostate cancer treatment market in China valued at 8.1 billion yuan in 2022, dominated by other established drugs [12][13]. Future Outlook - Analysts predict that Haichuang Pharmaceutical may not achieve profitability until 2027, with a consensus net loss forecast of 219 million yuan for 2025 [13].

Group 1 - HaiChuang Pharmaceutical (688302.SH) reported its Q3 2025 results on October 31, 2025, with 11 institutional investors holding a total of 34.54% of the company's shares, amounting to 34.2005 million shares [1] - The top ten institutional investors collectively hold 34.42% of the shares, with a decrease of 2.15 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, Penghua Innovation Growth One-Year Holding Mixed A, reported a slight decrease in holdings compared to the previous quarter [2] - A total of 78 public funds did not disclose their holdings this quarter, including notable funds such as Yinhua Digital Economy Stock Initiation A and CITIC Construction Investment Medical Reform A [2]

Core Viewpoint - The company, Xi'an High Voltage Electrical Research Institute Co., Ltd., has shown significant growth in revenue and net profit for the first nine months of 2025, indicating a strong performance in the electrical inspection and testing services sector [2]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 651 million yuan, representing a year-on-year growth of 15.05% [2]. - The net profit attributable to the parent company for the same period was 198 million yuan, reflecting a year-on-year increase of 21.28% [2]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 8.45% to 11,200, while the average circulating shares per person increased by 9.23% to 14,019 shares [2]. - The company has distributed a total of 280 million yuan in dividends since its A-share listing [3]. Financing and Trading Activity - On October 30, the company's stock price fell by 1.97%, with a trading volume of 92.23 million yuan [1]. - The financing buy-in amount for the company on the same day was 12.38 million yuan, with a net financing buy of 1.49 million yuan, indicating active trading [1]. - The total financing and securities lending balance reached 138 million yuan, accounting for 4.20% of the circulating market value, which is above the 80th percentile of the past year [1].

Core Viewpoint - Haichuang Pharmaceutical (688302) reported significant revenue growth in Q3 2025, driven by the launch of its first Class 1 new drug, HC-1119, for prostate cancer treatment, marking its entry into commercialization [1] Group 1: Financial Performance - For the first nine months of 2025, the company achieved revenue of 23.35 million yuan, a year-on-year increase of 21,180% [1] - The net loss narrowed to 99 million yuan from a loss of 154 million yuan in the same period last year [1] Group 2: Product Development and Market Entry - The drug HC-1119 was approved for sale in late May 2025, generating its first sales revenue [1] - HC-1119 has been included in the 2025 edition of the CSCO Prostate Cancer Diagnosis and Treatment Guidelines, gaining clinical recommendation status [1] - The product has passed the initial review for inclusion in the national medical insurance directory, which could enhance drug accessibility and market penetration [1] Group 3: Market Potential - Prostate cancer is a prevalent cancer among men in China, with 134,000 new cases reported in 2022, indicating a large and growing patient base [1] - The domestic market for second-generation anti-androgens is projected to exceed 4 billion yuan by 2024, with an estimated overall market size of 50 billion yuan by 2030 [1] Group 4: Sales Strategy - The company employs an innovative "self-operated + CSO" dual-track model, supported by a "medical-market-access-sales" four-wheel drive strategy [2] - A robust sales network has been established, covering over 500 hospitals and 240 DTP pharmacies across 30 provinces and cities in China [2] Group 5: Clinical Trials - The Phase I clinical trial for HP515, aimed at treating metabolic-associated fatty liver disease (MASH), has met its expected goals [2] - Initial results show significant improvements in multiple blood lipid indicators, with LDL-C reduction of 39%, TC reduction of 28%, and ApoB reduction of 41% at an 80 mg dosage [2] Group 6: Future Development Plans - The company is advancing to Phase IIa clinical trials for HP515, focusing on three main directions: combination therapy with GLP-1 for MASH, obesity treatment, and exploring combinations with its own oral small molecule GLP-1 receptor agonist [3]

证券代码：688302 证券简称：海创药业 公告编号：2025-046 海创药业股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 10 月 30 日 （二） 股东大会召开的地点：四川省成都市高新区科园南路 5 号蓉药大厦 1 栋 4 层公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 86 | | --- | --- | | 普通股股东人数 | 86 | | 2、出席会议的股东所持有的表决权数量 | 33,086,681 | | 普通股股东所持有表决权数量 | 33,086,681 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 33.4156 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 33.415 ...

中国成都市高新区天府一街 535 号两江国际 B 栋 33 层 610000 33/F, Building B, Twin Rivers International, No.535 Tianfu 1st Street, High-tech District, Chengdu 610000, China 电话 Tel: +86 28 6753 5588 传真 Fax: +86 28-6753 5588 电邮 Email: chengdu@tongshang.com 网址 Web: www.tongshang.com 北京通商（成都）律师事务所 关于海创药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：海创药业股份有限公司 根据《中华人民共和国律师法》《中华人民共和国公司法》（以下简称 "《公司法》"）《中华人民共和国证券法》《上市公司股东会规则》等法律、 法规和规范性文件以及《海创药业股份有限公司章程》（以下简称"《公司章 程》"）的规定，北京通商（成都）律师事务所（以下简称"本所"）接受海 创药业股份有限公司（以下简称"公司"）的委托，指派律师出席公司于 2025 年 10 月 30 日召开 ...

每经头条（nbdtoutiao）——多地出现"负电价"，既然卖电"不挣钱"，为何电厂不愿停机？ （记者 王晓波） 每经AI快讯，海创药业（SH 688302，收盘价：53.58元）10月30日晚间发布三季度业绩公告称，2025年 前三季度营收约2335万元，同比增加21180.28%；归属于上市公司股东的净利润亏损约9915万元；基本 每股收益亏损1元。 截至发稿，海创药业市值为53亿元。 ...

证券代码：688302 证券简称：海创药业 公告编号：2025-047 海创药业股份有限公司 自愿披露关于治疗代谢相关脂肪性肝炎（MASH）药物 HP515 临床Ⅰ期试验结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 近日，海创药业股份有限公司（以下简称"公司"）自主研发的拟用于治疗 代谢相关脂肪性肝炎（MASH，曾用名非酒精性脂肪性肝炎（NASH））的 HP515 临 床Ⅰ期试验（以下简称"该研究"）于近日达成预期目标。 现将相关情况公告如下： 一、HP515 项目最新临床研究数据 近日，一项评估 HP515 在健康受试者中单次和多次剂量递增给药的安全性、 耐受性、药代动力学、药效动力学及食物影响的 I 期临床试验（登记号： CTR20244934）已完成末例受试者出组，该试验包括单次剂量递增（SAD）、多次 剂量递增（MAD）及食物影响阶段，初步数据显示，HP515 在安全性、耐受性、 药代动力学及药效动力学方面均达到预期。 HP515 在单次给药递增至 200 mg、多次给药递增至 80 ...

证券代码：688302 证券简称：海创药业 海创药业股份有限公司 2025 年第三季度报告 海创药业股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 10,184,670.01 | 不适用 | 23,351 ...